Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ELUXADOLINE/TU:

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome. Keating GM et al. Drugs. (2017)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Lacy BE et al. Am J Gastroenterol. (2017)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Özdener AE et al. Drug Des Devel Ther. (2017)

Search results

Items: 1 to 20 of 51

1.

Irritable Bowel Syndrome: What Treatments Really Work.

Alammar N, Stein E.

Med Clin North Am. 2019 Jan;103(1):137-152. doi: 10.1016/j.mcna.2018.08.006. Review.

PMID:
30466670
2.

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.

Abel JL, Carson RT, Andrae DA.

Qual Life Res. 2019 Feb;28(2):369-377. doi: 10.1007/s11136-018-2008-z. Epub 2018 Sep 28.

3.

New treatments and therapeutic targets for IBS and other functional bowel disorders.

Simrén M, Tack J.

Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):589-605. doi: 10.1038/s41575-018-0034-5. Review.

PMID:
29930260
4.

Sphincter of Oddi dysfunction: sphincter of Oddi dysfunction or discordance? What is the state of the art in 2018?

Hyun JJ, Kozarek RA.

Curr Opin Gastroenterol. 2018 Sep;34(5):282-287. doi: 10.1097/MOG.0000000000000455. Review.

PMID:
29916850
5.

Evaluation of Eluxadoline Effect on Cardiac Repolarization.

Bonifacio L, Hunt TL, McIntyre G, Dove LS, Covington PS.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):727-736. doi: 10.1002/cpdd.453. Epub 2018 Apr 16.

6.

Advancements in drug development for diarrhea-predominant irritable bowel syndrome.

Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F.

Expert Opin Investig Drugs. 2018 Mar;27(3):251-263. doi: 10.1080/13543784.2018.1442434. Epub 2018 Feb 22. Review.

PMID:
29451407
7.

Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.

Harinstein L, Wu E, Brinker A.

Aliment Pharmacol Ther. 2018 Mar;47(6):809-815. doi: 10.1111/apt.14504. Epub 2018 Jan 19.

PMID:
29349789
8.

High throughput μ-SPE based elution coupled with UPLC-MS/MS for determination of eluxadoline in plasma sample: Application in pharmacokinetic characterization of PLGA nanoparticle formulations in rats.

Iqbal M, Ezzeldin E, Al-Rashood KA, Al-Shdefat R, Anwer MK.

J Pharm Biomed Anal. 2018 Feb 5;149:172-178. doi: 10.1016/j.jpba.2017.10.024. Epub 2017 Oct 28.

PMID:
29121571
9.

New therapies in Irritable Bowel Syndrome: what works and when.

Craig O.

Curr Opin Gastroenterol. 2018 Jan;34(1):50-56. doi: 10.1097/MOG.0000000000000411. Review.

PMID:
29095765
10.

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Özdener AE, Rivkin A.

Drug Des Devel Ther. 2017 Sep 26;11:2827-2840. doi: 10.2147/DDDT.S127405. eCollection 2017. Review.

11.

Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.

Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Oct;112(10):1619-1620. doi: 10.1038/ajg.2017.257. No abstract available.

PMID:
28978951
12.

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article.

Chen L, Ilham SJ, Feng B.

Anesth Pain Med. 2017 Jan 25;7(2):e42747. doi: 10.5812/aapm.42747. eCollection 2017 Apr. Review.

13.

Τ Eluxadoline for IBS-D.

[No authors listed]

Drug Ther Bull. 2017 Aug;55(8):91-92. doi: 10.1136/dtb.2017.8.0515. No abstract available.

PMID:
28808082
14.

Eluxadoline for IBS-D.

[No authors listed]

Drug Ther Bull. 2017 Aug;55(8):90-93. doi: 10.1136/dtb.2017.8.0514. Review.

PMID:
28808081
15.

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.

Vera I, Júdez FJ.

Rev Esp Enferm Dig. 2017 Nov;109(11):788-794. doi: 10.17235/reed.2017.5078/2017. Review.

16.

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.

Marbury TC, Berg JK, Dove LS, Covington PS.

J Clin Pharmacol. 2017 Nov;57(11):1454-1459. doi: 10.1002/jcph.964. Epub 2017 Jul 18. No abstract available.

17.

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Keating GM.

Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7. Review.

PMID:
28493170
18.

In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.

[No authors listed]

Med Lett Drugs Ther. 2017 Apr 24;59(1519):70. No abstract available.

PMID:
28419076
19.

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.

Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Jun;112(6):924-932. doi: 10.1038/ajg.2017.72. Epub 2017 Apr 18. Erratum in: Am J Gastroenterol. 2017 Jul;112(7):1210.

20.

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

Chey WD, Dove LS, Andrae DA, Covington PS.

Aliment Pharmacol Ther. 2017 May;45(10):1319-1328. doi: 10.1111/apt.14031. Epub 2017 Mar 22.

Supplemental Content

Loading ...
Support Center